Overview

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or without a BRAF inhibitor. GSK1120212 is a potent and highly selective inhibitor of MEK activation and kinase activity.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Trametinib